Alexion Pharma (ALXN) Tops Q3 EPS by 12c, Sales Miss; Bumps Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharma (ALXN) Threat From Amgen (AMGN) More Serious Than Previous Thought - Piper Jaffray
October 30, 2017 4:46 PM EDTPiper Jaffray maintains Overweight on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $170.00.
Analyst Chris Raymond says the threat from Amgen biosmiliar alternative to Soliris may be more credible and NT that previously suspected given what appears to be significant activity in Europe.... More
Alexion Pharmaceuticals (ALXN) PT Lowered to $159 at Stifel on 3Q Report; 'gMG Launch and P1/2 ALXN1210 Data Are Near-Term Catalysts'
October 27, 2017 11:11 AM EDTStifel lowered its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $159.00 (from $165.00) while maintaining a Hold rating, following the company's third quarter earnings report.
Analyst Stephen Willey notes a cautious outlook on the shares, commenting that "overall net product volume growth increased 9% y/y... More
Alexion Pharmaceuticals (ALXN) PT Raised to $122 at Jefferies Following 3Q
October 27, 2017 8:45 AM EDTJefferies raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $122.00 (from $121.00) while maintaining a Hold rating following the company's 3Q. ~In-line Soliris sales of ~$756M offset by lower non-GAAP OpEx and taxes, resulted in higher non-GAAP EPS of $1.44 (vs. consensus of... More
